RxDoctor Payments Data

David Goldner, MD

Nephrology · Aurora, CONPI 1356441836

Payments from drug & device makers

$822in general payments, 2019–2025

Across 25 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$155
  • Nxstage Medical, Inc.$135
  • Vifor Pharma, Inc.$118
  • Bard Peripheral Vascular, Inc.$115
  • Novartis$80
  • Edwards Lifesciences$64
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$822 in reported general payments places this provider in the 45th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$81,424
Medicare patients
336
Services billed
1,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol20$29,458
JardianceEmpagliflozin19$15,977
KerendiaFinerenone14$12,494
Tacrolimus16$2,156
Torsemide93$2,013
Midodrine Hcl15$883
Calcitriol67$851
Doxazosin Mesylate44$809
Potassium Chloride22$716
Mycophenolate Mofetil14$655
Nifedipine ErNifedipine28$643
Irbesartan40$616
Losartan Potassium70$562
Valsartan12$361
Furosemide72$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$17$29,45820 claims
Boehringer IngelheimJardiance$17$15,97719 claims
BayerKerendia$155$12,49414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 152 nephrology providers in Colorado.

Other nephrology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →